Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551046 | 1.00 | HCRTR2 (0.42) | HCRTR2HCRTR1PIM1PIK3CAHSD11B1 | |
| SCHEMBL550176 | 1.00 | HCRTR2 (0.42) | HCRTR2HCRTR1PIM1PIK3CAHSD11B1 | |
| SCHEMBL2699847 | 0.90 | HSD11B1 (0.45) | HCRTR2HCRTR1PIK3CAHSD11B1CNR2 | |
| SCHEMBL551432 | 0.90 | HSD11B1 (0.45) | HCRTR2HCRTR1PIK3CAHSD11B1CNR2 | |
| SCHEMBL554434 | 0.90 | HSD11B1 (0.45) | HCRTR2HCRTR1PIK3CAHSD11B1CNR2 | |
| SCHEMBL2700334 | 0.90 | PIK3CA (0.39) | HCRTR2HCRTR1PIK3CAHSD11B1EGLN1 | |
| SCHEMBL550972 | 0.90 | PIK3CA (0.39) | HCRTR2HCRTR1PIK3CAHSD11B1EGLN1 | |
| SCHEMBL550971 | 0.90 | PIK3CA (0.39) | HCRTR2HCRTR1PIK3CAHSD11B1EGLN1 | |
| SCHEMBL2700330 | 0.90 | PIK3CA (0.39) | HCRTR2HCRTR1PIK3CAHSD11B1EGLN1 | |
| SCHEMBL550906 | 0.90 | PIK3CA (0.39) | HCRTR2HCRTR1PIK3CAHSD11B1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | HCRTR2 3116/4885HCRTR1 2917/4885PIM1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.